表紙
市場調査レポート

EpiCast Report:座瘡の疫学的予測

EpiCast Report: Acne - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 281803
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
EpiCast Report:座瘡の疫学的予測 EpiCast Report: Acne - Epidemiology Forecast to 2022
出版日: 2013年08月31日 ページ情報: 英文 48 Pages
概要

世界の主要6ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国)における10〜44歳の座瘡患者は、2012年には1億391万人、2022年には1億546万人に達すると推計されています。座瘡は命に関わる病気ではありませんが、社会心理的・経済的な負担となるため、高リスク集団に対する予防的処置や、効果的な方法による早期の治療介入が必要となります。

当レポートでは、世界の主要国における座瘡の発症状況と今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要

第3章 疫学

  • 疾患の概要
  • リスク要因と共存症
    • 家族歴:患者のリスクを4倍増させる
    • 食習慣:最も共通する憎悪要因
    • 喫煙と座瘡の関係性は不明
    • うつ・不安賞:座瘡患者に一般的な共存症
  • 世界的な傾向
    • 米国
    • 欧州主要5ヶ国
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
  • 予測の前提条件と手法
    • 米国
    • フランス
    • ドイツ
    • イタリア・スペイン
    • 英国
  • 座瘡の疫学的予測(今後10年間分)
    • 尋常性座瘡の有病者数
    • 年齢層別の有病者数
    • 男女別の有病者数
    • 年齢調整済みの有病者数
    • 重症度別の有病者数
  • 議論
    • 結論と疫学的傾向
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER034

Summary

Acne vulgaris (acne) is an inflammatory skin disease that affects nearly all adolescents and adults at some point in their lives. The clinical presentation of acne ranges from a mild comedonal form to severe inflammatory cystic acne of the face, chest, and back. Globally, acne has a lifetime prevalence of over 90% in people of all ages, and a point-prevalence of approximately 85% in the population ages 15-24 years.

GlobalData's epidemiological analysis forecasts an increase in the total prevalent cases of acne in people ages 10-44 years in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK), from 103.91 million prevalent cases in 2012 to 105.46 million prevalent cases in 2022, with a decadal growth rate of 1.5%. As GlobalData epidemiologists used steady prevalence proportions of acne over the forecast period, the growth in prevalent cases in each market can be attributed to the change in population demographics in people ages 10-44 years in the respective markets.

Although acne is not a life-endangering condition, it is associated with a huge psychosocial impact and economic burden. GlobalData's epidemiological forecast emphasizes the need for preventive measures that are directed towards high-risk groups and signifies the need for early intervention with the available effective treatments in order to tackle the increasing burden of acne.

GlobalData epidemiologists forecast the prevalent cases of acne in the 6MM from 2012-2022 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific prevalence of acne in the 6MM. Additionally, they further segmented the total prevalent cases of acne by severity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 6MM to allow for a meaningful comparison of the total prevalent cases of acne across these markets.

Scope

  • The Acne EpiCast Report provides an overview of the risk factors and global trends of acne in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of acne prevalent cases segmented by age (in five-year increments beginning at age 0 and ending at age 44 years), sex, and stage in these six markets.
  • The acne epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global acne market.
  • Quantify patient populations in the global acne market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for acne therapeutics in each of the markets covered.
  • Identify the percentage of acne prevalent cases by stage.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. A family history of acne increases the risk of acne by four times
    • 3.2.2. Diet is the most common aggravating factor of acne
    • 3.2.3. The relationship between smoking and acne is unclear
    • 3.2.4. Depression and anxiety are common comorbidities in acne patients
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
  • 3.5. Forecast Assumptions and Methods
    • 3.5.1. US
    • 3.5.2. France
    • 3.5.3. Germany
    • 3.5.4. Italy and Spain
    • 3.5.5. UK
  • 3.6. Epidemiology Forecast for Acne (2012-2022)
    • 3.6.1. Total Prevalent Cases of Acne Vulgaris
    • 3.6.2. Age-Specific Total Prevalent Cases of Acne Vulgaris
    • 3.6.3. Sex-Specific Total Prevalent Cases of Acne Vulgaris
    • 3.6.4. Age-Standardized Total Prevalence of Acne Vulgaris
    • 3.6.5. Total Prevalent Cases of Acne Vulgaris by Severity
  • 3.7. Discussion
    • 3.7.1. Conclusions on Epidemiological Trends
    • 3.7.2. Limitations of the Analysis
    • 3.7.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Acne
  • Table 2: Classification of Acne Severity
  • Table 3: 6MM, Sources of Acne Prevalence Data
  • Table 4: 6MM, Sources of Acne Severity Data
  • Table 5: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10-44 years, Both Sexes, N (Millions), 2012-2022
  • Table 6: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), (Row %), 2012
  • Table 7: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10-44 Years, N (Row %), 2012
  • Table 8: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10-44 Years, Both Sexes, N (Millions) (Row %), 2012

List of Figures

  • Figure 1: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10-44 years, Both Sexes, N (Millions), 2012-2022
  • Figure 2: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), 2012
  • Figure 3: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10-44 Years, N (Millions), 2012
  • Figure 4: 6MM, Age-Standardized Total Prevalence of Acne Vulgaris, Ages 10-44 Years, 2012
  • Figure 5: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10-44 Years, Both Sexes, N (Millions), 2012
Back to Top